Article 1 to 3 out of 3 for "BLP25 liposome vaccine"
Ordered by
Oncothyreon to receive milestone payment from Merck KGaA (16 May 2008)
Oncothyreon Inc. announced that it has completed the transfer of certain assays and manufacturing technology related to Stimuvax(R) (BLP25liposomevaccine... cancer vaccine designed to induce an immune response to cancer cells that express...
Merck KGaA Acquires Full U.S. Rights to BLP25LiposomeVaccine (30 Jan 2006) Merck to assume development costs and will pay royalties to Biomira Inc. Inc. to amend the licensing agreement for BLP25LiposomeVaccine (L-BLP25... to the vaccine except in Canada, where the companies share rights to the vaccine.... L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier...
Biomira and Merck KGaA Commence BLP25LiposomeVaccine Phase II Safety Study (25 Apr 2005)
Biomira Inc. and Merck KGaA announced the start of a Phase II, single-arm, multi-centre, open label study of BLP25LiposomeVaccine (L-BLP25). The trial... changes intended to secure the future commercial supply of the vaccine. Enrollment...
Top